BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26192147)

  • 1. Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis.
    Berry K; Lerrigo R; Liou IW; Ioannou GN
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):118-23. PubMed ID: 26192147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System.
    Lerrigo R; Beste LA; Leipertz SL; Green PK; Lok AS; Kogut MJ; Ioannou GN
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):667-75. PubMed ID: 26886386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK; James PD; Sniderman KW; Wong F
    J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation.
    Ronald J; Wang Q; Choi SS; Suhocki PV; Hall MD; Smith TP; Kim CY
    Diagn Interv Imaging; 2018 Mar; 99(3):163-168. PubMed ID: 29154015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
    United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors.
    Luca A; Miraglia R; Maruzzelli L; D'Amico M; Tuzzolino F
    Radiology; 2016 Aug; 280(2):622-9. PubMed ID: 26982564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis.
    Dhanasekaran R; West JK; Gonzales PC; Subramanian R; Parekh S; Spivey JR; Martin LG; Kim HS
    Am J Gastroenterol; 2010 Mar; 105(3):635-41. PubMed ID: 19904245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
    Wei J; Li H; Li C
    J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis.
    Berry K; Taylor J; Liou IW; Ioannou GN
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):585-93. PubMed ID: 25459555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Standardized Assessment of Functional Disability Predicts 1-year Mortality in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites.
    Grunwald D; Tapper EB; Jiang ZG; Ahmed M; Malik R
    J Clin Gastroenterol; 2016 Jan; 50(1):75-9. PubMed ID: 25984975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transjugular intrahepatic portosystemic shunt in refractory hydrothorax - a contribution to an unexplored indication.
    Campos S; Gomes D; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):661-6. PubMed ID: 27002676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.
    Heinzow HS; Lenz P; Köhler M; Reinecke F; Ullerich H; Domschke W; Domagk D; Meister T
    World J Gastroenterol; 2012 Oct; 18(37):5211-8. PubMed ID: 23066315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a transjugular intrahepatic portosystemic shunt combined with autologous bone marrow cell infusion in patients with decompensated liver cirrhosis: an exploratory study.
    Huang M; Feng Z; Ji D; Cao Y; Shi X; Chen P; Wang P; Tang M; Liu K
    Cytotherapy; 2014 Nov; 16(11):1575-1583. PubMed ID: 25287603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation.
    King A; Masterton G; Gunson B; Olliff S; Redhead D; Mangat K; Oniscu G; Hayes P; Tripathi D
    Liver Transpl; 2011 Jul; 17(7):771-8. PubMed ID: 21714062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
    Membreno F; Baez AL; Pandula R; Walser E; Lau DT
    J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of transjugular intrahepatic portosystemic shunt (TIPS) alone versus TIPS combined with embolotherapy in advanced cirrhosis: a retrospective study.
    Xiao T; Chen L; Chen W; Xu B; Long Q; Li R; Li L; Peng Z; Fang D; Wang R
    J Clin Gastroenterol; 2011 Aug; 45(7):643-50. PubMed ID: 21301360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indicators for longterm survival after the transjugular portosystemic intrahepatic shunt procedure].
    Kirchhoff TD; Rosenthal H; Merkesdal S; Ockenga J; Manns MP; Galanski M; Caselitz M
    Radiologe; 2002 Sep; 42(9):745-52. PubMed ID: 12244477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.